Imaged guided transarterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for hepatic metastases from melanoma: early outcomes from a multi-institutional registry.

摘要: Patients with unresectable hepatic metastases from melanoma present a difficult clinical challenge due to lack of locoregional control and poor response systemic chemotherapy. This study aims examine the early outcomes novel treatment drug-eluting beads loaded doxorubicin (DEBDOX) delivered via image guided transarterial chemoembolization. A multicenter prospective open registry hepatic-directed therapy was reviewed. Six patients underwent 12 DEBDOX treatments for liver-predominant, melanoma. adverse events (grade 1 or 2) were exhibited in three most commonly emesis, nausea, pain. Over median follow-up months (range: 6-17), rates 100 per cent, 83 60 cent observed at 3, 6, 9 respectively, based on standardized computed tomographic criteria. survival 12.3 after initial observed. Initial results liver-directed hepatic-dominant metastatic disease demonstrate that this is safe well-tolerated option favorable characteristics point follow-up. Salvage should be considered multidisciplinary dilemma.